TW201132341A - Medicine compositions for treating urinary system - Google Patents

Abstract

This invention provides medicine compositions for treating urinary system, which is used to carry a carbon material containing 60 wt% or more of carbon in a water-containing carrier so as to make both form a medically acceptable water-containing carrier that carries carbon. The carbon material in each dose of medicine compositions of water-containing carrier that carries carbon is in the range from 0.1g/ml to 500 mg/ml, and the diameter of the carbon material is between 2nm and 2mm. The carbon material is further combined with metal particles selected from one of silver, platinum, gold, zinc or copper, or the group composed of these metals. The diameter of the metal particle is between 2 nm and 2 mm. The carbon material, or the carbon material combined with metal particles, contained in the medicine compositions can contact with the bladder or related organs inside animal, and have the functions of disinfection and lowering the cystitis, can control infection effectively and prevent the repetitive occurrence of cystitis, make the surface wound to be healed quicker and ease the disease of the cystitis sufferer. It can also be used regularly in concert with the medical personnel to keep the urinary system free of bacteria and prevent the occurrence of bacteriuria, cystitis and pyelonephritis.

Description

201132341 VI. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a pharmaceutical composition, which further enables the carbon material to be in an aqueous carrier to form a pharmaceutically acceptable carbon-loaded material. An aqueous carrier for treating a pharmaceutical composition of the urinary system. [Prior Art] According to the conventional urinary tract disease, cystitis or urinary tract infection is often caused by bacteria, chemicals, radiation, anticancer drugs or infection by exogenous bacteria, or It will be caused by the infiltration of drugs, resulting in bacterial invasion, and it is especially good for women or patients with catheters. The simplest way to judge whether or not the phenomenon of bacteriuria occurs is whether or not Produce cystitis, that is, the amount of bacteria per ml of the exhibition liquid is greater than CFU, wherein there are about 98% of the bacteria inhabitants at the distal 2 cm of the male urethra, and 49% in the 5 cm; * The rate of bacterial colonization may be higher in women. Therefore, when the amount of bacteria in the urine is too high, there is bladder inflammation or pyelonephritis; and according to the statistics of Taiwan's intensive care in 2007, urinary tract infections account for 37.5% of the hospital infections, regardless of疋w learning center or regional hospital, urinary tract infection is the highest in the hospital intensive care unit in Taiwan, so the current urinary system diseases caused by bacterial infections in all age groups can be seen. Invasive treatment of urinary tract infections, catheterization or cystoscopy is the most common medical operation in hospitals and the main cause of exogenous infections, as it brings bacteria 201132341 into Bladder, and at the same time may cause ascending bacterial infection, which may cause bacterial cystitis, severe cases often cause acute cystitis or nephritis; for example, the most common bacterial depilation, its inflammation is in the department In the mucosa of the bladder, redness, swelling, vascular congestion, etc., and interstitial cystitis are caused by inflammation between the lower layer of the mucosa and the muscle layer. Therefore, when cystitis occurs, it usually causes bladder discomfort and Pain, and frequent urinary and urinary urgency-related conditions, and when the cystitis is not treated properly, the call often results in severe silk in the bladder, which may cause the kidneys of the patient to lose function. There is a danger of dying from sepsis. At present, the treatment of cystitis mainly includes the treatment of cystitis such as drug therapy, antibacterial bladder lavage or drip administration, wherein either the instillation method is used as a monotherapy or the drip method is used. Combination therapy with other treatments, or sequential therapy combining the above three, such as monomethylopia, cl〇rpactin, heparin, transglutamate, Doxorubicin, chondroitin sulfate, sodium bicarbonate 'silver nitrate, pentosan sodium polysulfate, sodium cromoglycate, penicillin, nitrofurazone, gentamicin or weak protein silver, etc., mostly with bladder mucosa and interstitial tissue layer The goal of treating cystitis is to relieve the symptoms of cystitis such as pain, uric acid and urgency, and the techniques for preventing bacterial infections in the urinary tract are antibiotic prevention, catheterization, silver or silver plating. Catheter technology, etc., however, in the two cystitis treatments or techniques to prevent bacterial infections of the urinary tract, it is rare to have a remission effect for a sustained period of time' or for long-term treatment and use of the 201132341 The prevention technique 'and a side effect at the same time during treatment. [Summary of the Invention] However, for the treatment of cystitis, if it relies solely on anti-g drugs to treat infection, and the antibacterial drug can not immediately repair the bladder mucosa and interstitial tissue, it does not touch the fruit; The damaged bladder mucosa and (4) tissues can be effectively repaired, and the cause of the infection can be identified and the necessary treatment can be given in time to control the infection more effectively, prevent the repeated attacks, and promote the healing of the bladder surface injury. It is necessary to soothe the symptoms of patients with cystitis. The present invention provides a (four) composition for treating a urinary system, wherein a carbon material having a carbon content of 60% by weight or more is contained in an aqueous carrier, so as to form an acceptable water-bearing carbon material. a carrier, and the aqueous carrier carrying the carbon material comprises a carbon material per unit dose between 〇·1 mg/ml and 1〇〇mg/ml, and the diameter of the carbon material is between 2 nm and Between 2 mm, the carbon material further contains metal particles selected from the group consisting of silver, gold, zinc or copper - or a group thereof, and the diameter of the metal particles is between 2 nm and 2 mm between. The invention provides a pharmaceutical composition for treating a urinary system, wherein the carbon material or the carbon material combined with the metal particles can be contacted with the bladder and related tissues in the animal for treating and preventing cystitis. Acute cystitis 'chronic cystitis, hemorrhagic cystitis, bacterial cystitis, gas-induced cystitis, interstitial cystitis, bladder or urethral wound patients, 201132341 patients with urinary tract infections' can effectively control infection, Prevents the onset of cystitis and promotes wound healing on the surface of the bladder, so that the symptoms of patients with cystitis can be relieved. [Embodiment] The present invention is a preferred embodiment of a pharmaceutical composition for treating a urinary system, wherein the pharmaceutical composition for treating a urinary system is mainly composed of a carbon material having a carbon content of 60 wt% or more by weight - An aqueous carrier which forms an acceptable aqueous carrier carrying a carbon material selected from the group consisting of carbon fibers, activated carbon fibers, activated carbon, graphite, expanded graphite, carbon nanotubes, and carbon spheres. One of the carbon spheres or carbon black, or a carbon material of the group, and the difference between the Wei and the test is between 2 () coffee and 2 coffee, and the structure and specific surface area value (10) τ) are 2〇仏~side

Between the crucibles, wherein the storage system of the preferred embodiment of the present invention is activated carbon fiber powder, the weight percentage of carbon content is above and the structure and specific surface area value (BET) is m2/g~ The 'simultaneous' HF aqueous carrier is selected from the group consisting of a buffer, an antibiotic agent, and a cystitis, or a combination thereof, and the water-containing ship of the ft. Contains Q. Above = for each unit of Xie. The feeding between the .lmg^^; the other part of the second embodiment of the present invention is the preferred embodiment of the invention, and the resulting effect is the preferred embodiment, so it will not be described again, the towel, the carbon material 201132341 is further combined with a a metal particle selected from the group consisting of small particles of a group of silver, platinum, palladium, gold, zinc or copper or a group thereof, and the diameter of the metal particle is between 2 nm and 2 mm, And the weight percentage of the metal particles to the weight of the carbon material is 2% by weight or less, and the weight percentage of the small particle metal system to the weight of the carbon material in the second embodiment is 5 wt% or less 'the small particle metal and carbon The materials are combined and then loaded on an aqueous carrier to form a pharmaceutical composition for treating the urinary system; in addition, the antibiotic agent of the aqueous carrier is selected from

Tr i methopr i m-su1farae-thoxazo1e (TMP-SMX),

Trimethoprim (TMP), sulfame-thoxazole (SMX), fluoroquinolones, Ciprofloxacin, 〇n〇xacin,

An antibiotic agent of one or a combination of Cephalexin and tetracycline; and the therapeutic agent for cystitis of the aqueous carrier is selected from the group consisting of di-T-Athene, Clorpactin, Heparin, Hyaluronic Acid, A Pharmaceutics, detoxification soft # 骨素, sodium bicarbonate, silver nitrate, pentosan sodium polysulfate, sodium cromolyn, penicillin, nitrofurazone, gentamicin or weak protein silver or a combination thereof for the treatment of bladder de-inflammatory agents. The reason is that the material of the composition of the medicine or the carbon material combined with the metal particles can be contacted with the bladder and related tissues in the animal to treat and prevent cystitis, acute cystitis, chronic cystitis, Hemorrhagic cystitis, bacterial cystitis, gas-producing cystitis, interstitial cystitis, patients with wounds in the bladder or urethra, and patients with urinary tract infections can effectively control the infection of 201132341 and prevent the recurrence of cystitis. The patient with cystitis is relieved. Viewing the surface of the wound sore, = Jin- (four) Jieshuer complex, the lion's technical solution and the effect achieved by the system, according to the use of the invention ^ to describe, I believe that each can be richer and more specific As described below, Tian

Please refer to the figures to the fifth figure. The carbon material of the pharmaceutical composition is the active rhyme dimension, produced and sold by TAIWAN CARBON TECHNOLOGY CO., LTD. = Activated carbon fiber 'and grinded to a particle size of 5Q / / m to (10) Qing, its slave material's knot surface area value is coffee m2 / g ~ 2 () () () M, and this month is better, And the aqueous carrier of the example is a buffer, and the buffer is further free of water. The carbon material is added to the buffer to be fully stirred to form an aqueous carrier carrying the anti-material, and The aqueous carrier of the broken material contains 0.2 mg/ml of carbon material per unit dose, and three female Sprague-Dawley rats are used, which weigh about 29 〇g, and are grouped into: (l), Ml-l (Nornial): Normal rats, no injection of induced inflammatory agents, and no induction of bladder inflammation. (2), M1-2CLPS): Injects an inflammatory agent to induce inflammation of the bladder. (3), M1-3 (LPS-ACF): injection induces an inflammatory agent, induces inflammation of the bladder, and then injects an aqueous carrier of carbon material into the bladder for treatment. Before the start of the experiment, the rats were anesthetized with urethane. After confirming that the rats had been anesthetized, they were taped to the soft board 201132341 and then the polyethylene tube (PE-50). Perform the following steps: After the above procedure is completed, perform the following steps: First, the two rats in the M1-2 (LPS) group and the M1-3 (LPS-ACF) group are injected with the bowl of protamine. The sheds are like the New Zealand, ps) into the bladder of these rats, and first cause the M1-2 (LPS) group and Ml-3 (LPS-ACF), and the two rats have their bladder mucosa injured. Re-injection induces an inflammatory agent, and the present invention is preferred to perform an inflammation of the sputum injection _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Inflammation occurs in the bladder of the mouse. In the injection of sulfuric acid fish (10) for 45 minutes, the hydrophobic physiological saline (10) (4) cleans the bladder, controls the damage range, and prevents the protamine sulfate from further injuring the bladder interstitial cells. After washing the bladder with π, re-injection Inducing an inflammatory agent, endotoxin Wo e. 亚. Sub-reduction of the bladder production of these rats Inflammation occurs, and every half an hour ♦ injection-reading materials are paid twice in total, and then the bladder is washed with physiological saline = nnauallne. ▲ Hide the M1-3 (the LPS side group of Jingjing the pharmaceutical composition, and the material composition of the carbon material of the material is added to the buffer, the pot concentration per unit dose is 4mg/20ml, and for I· European rats were only injected with physiological saline, and injected once every half hour. The mounds were injected four times. After one hour, the three rats collected the second urine separately, m 9 201132341 after a total of 24 hours. The bladders of the three rats were collected for weighing and the bladder sections of the three groups of rats were stained with & E staining pathology. Please refer to the first figure, analyze the first collection of urine, the

The Ml-1 (Normal) group was the control group, so it was not collected, and the rats in the m1_2 (lps) group induced the inflammatory agent up to 9·6 EU/ml, and the M1-3 (Lps_ACF) group induced the inflammatory agent up to 36. 〇Eu/ml; and after three hours and then analyze the second job urinary wealth, the M1-KN(10)al) group is the control group, and the induced inflammatory agent is UEU/m, the M1-2 (LPS) In the case of the induced inflammatory agent, P is extravagant to 1.8 EU/ml. The group of LPS-ACF is injected into the pharmaceutical composition containing the aqueous carrier containing the carbonaceous material, and the inflammatory agent is induced. After dropping to l.0EU/ml, three rats in the MM (N〇rmal) group, m-2 (10) group and Ml-3 (LPS-ACF) group were compared to induce inflammatory agents. . As a result, it can be known that the _3 (Lps_Ac{?) group knows that _2 (lps), and the main irritant is inflamed, and the inflammatory agent content I in the first urine is ^Ε_, After the induced inflammatory agent was naturally metabolized in the rat, the second time in the urine, the hair was induced to still remain in the U Ε _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Inducing inflammatory agent lure u in the first urine, the concentration of the inflammatory agent S reaches 36. 0 m', and injects the medicinal composition of the aqueous carrier containing the carbon material to induce the inflammatory agent content in the secondary urine. The medical system that has been reduced to 1 〇 〇 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 诱导 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 Please refer to the figure--the figure shows the therapeutic effect of the pharmaceutical composition of the aqueous carrier containing the carbon material by the weight of the bladder of the three rats. The Ml-2 (LPS) group The weight of the rat in the bladder was 177 3 mg, and the rats in the m-3 (LPS-ACF) group were induced by the injection-induced inflammatory agent to induce bladder resuscitation, and were injected with the inclusion of The medical composition of the carrier is treated, and the rats in the M1-3 (LPS_ACF) group are deprived of the summer P to 134.8 mg after the treatment, which means that the aqueous carrier carrying the carbon material is injected. The pharmaceutical composition has been produced to treat edema caused by cystitis. In order to further understand the internal condition of the rat bladder, please refer to the second figure, which is the normal bladder η & E stained section of the Ml-1 (Normal) group, which can be clearly seen from the second figure. Under normal circumstances, the bladder surface of the bladder surface is seen to be very smooth; see the third figure, which is the Ml-2 (LPS) group of rats induced by inflammatory agents induced inflammation after the bladder After the & E staining section, it can be seen that the large milk in the M1-2 (Lps) group causes white blood cells to accumulate in the interstitial layer of the bladder below the mucosa due to inflammation, and as shown in the fourth figure, the M1_2 (LPS) A very serious internal hemorrhage was observed in the internal tissues of the rats in the group, as shown in the fifth figure, the rats in the W-3 (LPS-ACF) group were induced to be inflamed by the induced inflammatory agent, endotoxin, and The treatment of the pharmaceutical composition of the aqueous carrier carrying the carbon material 'the bladder Η & E stained section is compared with the bladder mucosa tissue of the Ml-3 (LPS-ACF), and the second figure of the Ml-1 (Normal) group of normal rats 201132341 bladder mucosal domain can be now both miscellaneous, the (four)

& - - Lunin » # ΐ ^The concentration of the drop-off content before the serum towel is mainly used to determine the tear

〆^ ^ 1 viMuimau 殂 is a normal rat with a pre-aged concentration of 〇. 〇 21 ng/ml; M2_2 aps) is a group of rats with induced inflammatory agents and inflammation. Increased to 0·_ ng/ml; and M2-3 (LPS-ACF) group is induced by inflammatory agents induced inflammation and neonatal treatment, the pre-aged concentration is 〇.〇2 ng/ The ml's comparison showed that the M2_3 (Lps-ACF) group had the same calcitonin concentration as the M2-1 (Normal) group, and the M2-2 (LPS) group had the bladder weight of 177. The bladder weight of rats in the β mg and M2 -3 (LPS-ACF) groups has dropped to 138 after treatment, which can be found that the composition of the water-containing dragons with carbon (4) does have a bladder inflammation 201132341. Efficacy. Referring to the seventh to the ninth riding, it is the pathological tissue section of the bladder and the E staining of the different groups of rats. Please refer to the seventh figure for the H (Ν_υ group) The mouse-cyst tissue section can be = very smooth bladder thin' and the bladder tissue section of the rat in the Μ2-2 (LPS) group shown in the first figure can be seen from the left side of the financial report. It can be seen that the (B)-LPF-ACF group of rats can see a smooth bladder mucosal surface, and there is no serious inflammation of the bladder such as white blood cell aggregation and bleeding. Because I, the table should not contain The pharmaceutical composition of the aqueous carrier of the carbon material produces a therapeutic effect on the bladder of the rat inflammation. Further, as shown in Fig. 12 to Fig. 12, it is the same type of j bladder amp & Ε staining The main embodiment of the invention is the same as the preferred embodiment of the invention, so it will not be described again. Among them, the ship -3 (8) fresh implanted m read the miscellaneous medical surplus system is "human brother two embodiment" And the main purpose is to use metal particles and the carbon material, and then carry it in the The carrier forms a medical group j for treating cystitis, and the metal particles selected in the second embodiment of the present invention are nano-sized soils and silver particles, and the four first-parameters (four) and ten-graphs are M3--(10) The ancestors, normal rats, their bladder sputum & E stained sections, from the tenth figure can be seen "bonfire, hot water swelling and no internal bleeding, and see the eleventh figure can see M3-2 In the (LPS) group, after induction of inflammatory agents to induce bladder inflammation, the 201132341 picture can be seen in the white blood cell aggregation, edema and internal bleeding and other serious bladder inflammation. Please refer to Figure 12 to see M4-3CLPS- ACF) rats were induced to inflame by inducing inflammatory agents, and then treated with carbon material containing silver-containing metal particles. From the tenth-graph, it can be found that there is no serious accumulation of white blood cells, edema and internal bleeding. Inflammation, therefore, the pharmaceutical composition formed by combining the carbon material with the silver-containing metal particles has the effect of sterilizing and reducing the symptoms of cystitis. By the above description, the advantages and the achievable effects of the present invention can be achieved. As follows: 1 The pharmaceutical composition of the present invention for treating the urinary system, the carbon material is carried on an aqueous carrier to form a pharmaceutically acceptable aqueous carrier carrying the carbon material, and is acceptable for the bladder mucosa, and further The phenomenon of soothing cystitis is accompanied by a long-acting therapeutic effect. 2. The pharmaceutical composition for treating the urinary system of the present invention, wherein the aqueous carrier is contained in a pharmaceutically acceptable carrier The aqueous carrier of the broken material is further capable of repairing the bladder mucosa to produce a further therapeutic effect. 3 The pharmaceutical composition for treating the urinary system of the present invention, the metal particles combined with the carbon material are selected from the group consisting of silver, platinum, palladium, gold a metal particle of one or a group of zinc or copper, and the diameter of the metal particle is between 2 nm and 2 mm, and the carbon material is combined with the metal particles of the nanometer to enhance the sterilization thereof. Reduce the effects of symptoms of cystitis. 14 201132341 4. The medical composition for treating the urinary system of the present invention has a relatively high structure and specific surface area value, and good biocompatibility, and can actively adsorb fine mites and cause pathogenic bacteria in the bladder. The amount is rapidly reduced to below 105 CFU and adsorbs bacterial exotoxin and endotoxin, and harmful substances. And the urine is excreted from the body to achieve a preventive effect. In summary, the present invention has excellent advancement and practicability in similar products, and at the same time, inspecting domestic and foreign technical materials on such structures, the literature does not find that the same structure exists first, , the present invention patents, the practice of the "please." ^ ^ | · 隹 The above is only one of the preferred embodiments of the present invention, so the application of the specification of the present invention and the scope of the patent equivalent structure The change is intended to be included in the scope of the patent of the present invention. 201132341 [Simple Description of the Drawings] The first figure is a comparison of the induced inflammatory agent content test and the bladder weight in the urine of each group of rats according to a preferred embodiment of the present invention. The figure is a H&E stained slice of the normal rat of the Ml-1 (Normal) group, which has a blood vessel (Bl〇〇dvessei, BV) and epithelial cells constituting the mucosa (in the preferred embodiment of the present invention). Epithelium, Ep), Muscle 'M), Connective tissue (CT),

And the interstitial layer (Lamina propria, Lp). The second figure is a micrograph of the bladder Η & E staining of the Ml-2 (LPS) group after induction of inflammation and inflammation by the rat in the preferred embodiment of the present invention, and the surface of the bladder has been inflamed, and white blood cells have appeared. (Whitebl〇〇dcells, WBC) aggregation, edema (Edema) and bleeding (Bleed) phenomenon. The fourth figure is the first figure of the figure (4) ((10) group of the tissue under the epithelial membrane and the E staining slice diagram, and shows the phenomenon of serious internal bleeding. The fifth figure is the MI-3 of the preferred embodiment of the present invention. The rats in the (LSP-ACF) group were induced to have inflammation of the bladder, and then injected with the pharmaceutical composition of the aqueous carrier of the carbon material to treat the bladder Η & Ε stained slice. In the examples, each group of dancers (10) degrees and _ weight ratio shed. (Normal) group (LPS) group induced by the seventh figure is a preferred embodiment of the present invention, its normal rat bladder Η & Ε stained section Figure 8 is a preferred embodiment of the present invention. 16 201132341 Inflammatory agent induces bladder inflammation after inflammation of the bladder Η & E stained slice, and the left side of the figure can be found to be very serious edema. In a preferred embodiment of the present invention, the M2-3 (LPS-ACF) group is induced by an inflammatory agent to induce inflammation of the bladder, and then injected into a medical composition containing an aqueous carrier carrying a carbon material, and the bladder Η & E stained slice is treated. The tenth figure is the M3-1 (Normal) group of the second embodiment of the present invention. Normal rat, its bladder Η & E stained section. Figure 11 is a second embodiment of the present invention Μ3-2 (LPS) group induced by inflammatory agents induced bladder inflammation, its bladder amp & Ε stained slice The white blood cell aggregation and internal hemorrhage can be seen on the left side of the figure. The twelfth figure is the second embodiment of the present invention. The Μ4-3 (LPS-ACF) group induces inflammation of the bladder by the induced inflammatory agent, and then injects the aqueous carrier carrying the carbon material. After the treatment of the medical composition, the bladder Η & Ε stained slice map. [Main component symbol description] "Learn" > "The invention"

Claims (1)

201132341 VII. Scope of application for patents: A pharmaceutical composition for treating the urinary system, which is characterized in that the carbon material having a weight percentage of 60 wt% or more is contained in an aqueous carrier An acceptable aqueous carrier carrying a carbon material, the surface of the paste, is between 2 nm and 2 coffee cups; thereby, the pharmaceutical composition of the aqueous carrier carrying the broken material is The carbon material is in contact with the bladder and related tissues in the animal, p: the symptoms of low cystitis. 2. The pharmaceutical composition for treating the urinary system according to the scope of the application of the patent application, wherein the aqueous carrier carrying the carbon material comprises a carbon material of not more than 〇1 mg/ml per unit dose. 3. The pharmaceutical composition for treating the urinary system according to item 2 of the scope of the patent application 'in which the carbon-containing money body has a carbon (four) concentration is further advanced _ step system is per _ quantity 〇. i mg/ml between. 4. The pharmaceutical composition for treating the urinary system according to the scope of the patent application section wherein the weight percentage of the disc material of the carbon material is further more than 80 wt%. 5, according to the scope of application for patents! The pharmaceutical composition for treating the urinary system according to the item (8) is further characterized by a metal particle which is a metal particle which is far free of silver, turned over, gold, zinc or copper, or a composition thereof. And the diameter of the metal particles is between 2 and 201132341 2 mm' and the weight percentage of the metal particles to the weight of the broken material is 20 wt% or less. 6. The pharmaceutical composition for treating the urinary system according to claim 5, wherein the metal particles further comprise a weight percentage of the weight of the carbon material of 5 wt% or less. 7. The pharmaceutical composition for treating a urinary system according to claim 1, wherein the carbon material is selected from the group consisting of carbon fiber, reactive broken fiber, activated carbon, graphite, expanded graphite, carbon nanotubes, and nanocarbon. One of the balls, coke balls or stone anti-black or a group of carbon materials. 8. The pharmaceutical composition for treating the urinary system according to claim 1, wherein the diameter of the carbon material is further between 2 〇 nm and 2 删. 9. The pharmaceutical composition for treating the urinary system according to claim 1, wherein the aqueous carrier is selected from the group consisting of a buffer, an antibiotic agent, and a cystitis agent, or a combination thereof. 10. The pharmaceutical composition for treating the urinary system according to claim 9, wherein the antibiotic agent is selected from the group consisting of Trimethoprim-sulfame-thoxazole (TMP-SMX), Trimethoprim (TMP) ^ sulfame-thoxazole (SMX) > fluoroquinolones ' Ciprofloxacin ' Ofloxacin > Antibiotics for one of Cephalexin and tetracycline or a combination thereof. The medical composition for treating the urinary system according to claim 9, wherein the therapeutic bladder agent is selected from the group consisting of diterpenoids, oxyirpactin, heparin, and transparent Treatment of cystitis with acid, doxorubicin, chondroitin sulfate, sodium bicarbonate, silver nitrate, sodium pentosan polysulfate, sodium cromoglycate, penicillin, nitrofurazone, gentamicin or weak protein silver or a combination thereof . 12, according to the scope of application for patents! The pharmaceutical composition for treating the urinary system according to the item, wherein the structure and specific surface area (BET) of the carbon material are between 20 m2/g and 4000 m2/g. 13. The pharmaceutical composition for treating the urinary system according to claim 12, wherein the structure and specific surface area value (ΒΕτ) of the carbon material are further between 200 m2/g and 2000 m2/g. 14 kinds of medicinal urinary system medicinal composition, the main component of which is the weight percentage of carbon content in 6G (four) society carbon material contained in the water-water, so that the two form a coffee-acceptable carbon material An aqueous carrier, the carbonaceous material is combined with a metal, the metal particles occupying the weight of the carbon-containing material containing the rotating body is 2 () (four) or less, wherein the carbon material is selected from carbon fiber, active Carbon fiber, activated carbon, graphite, swelled stone, ink, tube, carbon fiber, coke ball or carbon black, or a group of carbon materials, and the direct control of the carbon material Between 2 nm and 2 mm; thereby, the medical composition containing the carbon material is brought into contact with the bladder and related tissues in the animal by the carbon material and the metal particle 20 201132341, thereby generating Sterilize and reduce the symptoms of cystitis. 15. The pharmaceutical composition for treating a urinary system according to claim 14, wherein the disc material further has a carbon content of 80 wt% or more, and the combined metal particles are selected from the group consisting of silver and platinum. , a small particle of a group of saturated or gold, zinc or copper, or a group thereof, and the diameter of the metal is between 5 nm and 2 mm, and the metal particles are in the weight of the carbon material. The percentage is less than 5 wt%. The pharmaceutical composition for treating the urinary system according to the fourth aspect of the patent application, wherein the aqueous carrier containing the carbon material comprises carbon ranging from 0.1 mg/ml to 500 mg/ml per unit dose. material. 17. The pharmaceutical composition for treating the urinary system according to claim 14, wherein the structure and specific surface area (βΕΤ) of the carbon material are further between 200 m/g and 2000 m2/g. The pharmaceutical composition for treating the urinary system according to claim 14, wherein the aqueous carrier is selected from the group consisting of a buffer, an antibiotic agent, and a cystitis agent, or a combination thereof. 19. The pharmaceutical composition for treating the urinary system according to claim 18, wherein the antibiotic drug is selected from the group consisting of Trimethoprim-sulfame-thoxazole (TMP-SMX), Trimethoprim (TMP), sulfame-thoxazole (SMX). , 201132341 fluoroquinolones > Ciprofloxacin > Ofloxacin' Cephalexin and tetracycline, or a combination thereof, antibiotic drug 0 20, according to the scope of claim 18, the pharmaceutical composition for treating the urinary system, wherein the treatment The bladder drug is selected from the group consisting of dimercaptopurine, Clorpactin, heparin, hyaluronic acid, doxorubicin, chondroitin sulfate, sodium bicarbonate, silver nitrate, sodium pentosan polysulfate, and color acid. A cystitis drug for treating one or a combination of sodium, penicillin, nitrofurazone, gentamicin or weak protein silver. 22 (5)